P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy study.

BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab (BVZ) lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since BVZ markedly reduces tumor edema, we asked whether the MI concentr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Steidl, E., Pilatus, U., Steinbach, J. P., Zanella, F., Ronellenfitsch, M. W., Hattingen, E., Bähr, O.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
P06 Biomarkers
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782594/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.096
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki